VJHemOnc Podcast

The treatment of aggressive lymphomas such as diffuse large B-cell has seen dramatic changes, and with the advent of bispecific monoclonal antibodies, there is hope for a wider demographic of patients.

Due to the COVID-19 pandemic, the 62nd American Society of Hematology (ASH) 2020 Annual Meeting and Exposition (ASH 2020) was held virtually – and it didn’t disappoint in the quality and breadth of data presented.

In this exclusive discussion leading experts Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, of Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK debate the latest in the treatment of lymphoma from the ASH 2020 virtual Annual Meeting and share how the new research and clinical updates can help improve patient management strategies in UK clinical practice.

The post The Lymphoma Sessions: ASH 2020 highlights appeared first on VJHemOnc.

The International Symposium on Hodgkin Lymphoma (ISHL) 2021 Hodgkin Lymphoma (HL) update gathered an international panel to discuss the most recent developments in HL, and provided a comprehensive update on current and emerging concepts. In this podcast, we spoke to Sven Borchmann, MD, of the University Hospital Cologne, Cologne, Germany, Paul Jan Bröckelmann, MD of the University Hospital of Cologne, Cologne, Germany, and Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, as they outline the latest thinking in HL, touching on the use of biomarkers in HL, first-line approaches as well as updates in relapsed/refractory disease.

The post Latest updates in Hodgkin lymphoma from ISHL HL 2021 appeared first on VJHemOnc.

The development of immunomodulatory agents and proteasome inhibitors alongside stem cell transplantation and chemotherapy has significantly improved the treatment options for patients with myeloma. Recently, B-cell maturation antigen (BCMA) has emerged as a promising target for myeloma treatment due to its selective expression in malignant plasma cells. Current work in this area focuses on determining the optimal combination of therapies, treatment strategies to overcome relapse, and clinical trials to aid the development of novel BCMA-targeted treatment modalities.

VJHemOnc is joined by Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, and Karthik Ramasamy, MD, MBBS, MRCP, FRCPath, PhD, of the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, to discuss the latest research in myeloma presented at the American Society of Hematology (ASH) 2020 virtual annual meeting. These leading experts share their insights into emerging data on newly diagnosed myeloma, combination therapies in the relapsed setting, and novel BCMA-targeted myeloma therapies currently undergoing clinical trials such as CAR-T, BiTEs, and antibody-drug conjugates.

The post The Myeloma Sessions: Post-ASH 2020 UK Discussion appeared first on VJHemOnc.

The European Group for Blood and Marrow Transplantation (EBMT) Trainee Committee was established in 2021 to address the needs of trainees in the field of bone marrow transplant and cellular therapy and provide advice and support for trainees. The group, composed of trainees, young investigators, and students, wants to encourage trainees to establish themselves within the EBMT community to help build a collaborative working relationship with other EBMT Committees and other associations and groups.

In this podcast, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Claire Horgan, Paediatric Haematology Trainee, UK, and Yasmina Serroukh, MD, PhD, University of Montreal, Montreal, Canada, discuss the recent EBMT Trainee Committee, highlighting its goals and upcoming activities. Additionally, the speakers review the first ever special session, ‘The EBMT for Trainees’, that took place during the EBMT Annual Meeting 2021.

The post The Post-EBMT for Trainees VJSessions appeared first on VJHemOnc.

The most common form of amyloidosis, light-chain (AL) amyloidosis, results from abnormalities in plasma cells causing them to produce abnormal amyloid fibrils made up of immunoglobulin light chains. These insoluble fibrils deposit extracellularly and accumulate within organs such as the heart, kidneys, liver, spleen, nervous system, and digestive tract, disrupting their structure and impairing their function. Historically, successful treatments for amyloidosis have been anti-plasma cell chemotherapies that reduce the production of amyloidogenic light chains. More recently, monoclonal antibody treatments such as daratumumab, evaluated in the ANDROMEDA trial, have demonstrated efficacy against malignant plasma cells. Current investigations are also exploring the ability of monoclonal antibodies to target and eliminate amyloid from organs.

In this podcast, we are joined by Morie Gertz, MD, MACP, of the Mayo Clinic College of Medicine, Rochester, MN, Vaishali Sanchorawala, MD, of the Boston University Medical Center, Ashutosh Wechalekar, MBBS, MD, FRPC, FRCPath, DM, of the National Amyloidosis Centre, London, UK, and Raymond Comenzo, MD, of the Tufts New England Medical Center, Boston, MA. These experts discuss highlights from this year’s virtual American Society of Hematology (ASH) meeting and exposition, such as results from the ANDROMEDA study, the use of monoclonal antibodies, and unmet needs in AL amyloidosis diagnosis and awareness.

The post Post-ASH Amyloidosis Session from VJHemOnc appeared first on VJHemOnc.